Purpose: End-of-life (EOL) chemotherapy has been described as the most widespread, wasteful, and unnecessary practice in oncology, with benchmarking aimed to reduce physician use of chemotherapy within 14 days of EOL. We evaluated the recent transformation of EOL chemotherapy and targeted therapy practices nationally.
Methods: In patients older than 65 years of age who died as a result of breast (n = 19,887), lung (n = 79,613), colorectal (n = 29,844), or prostate (n = 17,910) cancer between 2007 and 2013, we evaluated the guideline-benchmarked measure of chemotherapy use within 14 days of EOL in SEER-Medicare. Comparison outcomes were nonbenchmarked measures of chemotherapy and targeted therapy across time points within 6 months of EOL. Cochran-Armitage test was used to evaluate temporal trends. Multilevel logistic models and intraclass correlation coefficient was used to evaluate variation in EOL chemotherapy use at the physician level.
Results: From 2007 to 2013, chemotherapy within 14 days of EOL declined from 6.7% to 4.9% of patients (Ptrend < .001; ∆ = -1.8%). Similar declines occurred for chemotherapy within 1 month (Ptrend < .001; ∆ = -1.8%) and 2 months (Ptrend < .001; ∆ = -1.3%) of EOL. In contrast, chemotherapy within 4 to 6 months of EOL rose (Ptrend ≤ .04; ∆ = 0.7% to 1.7%), and 43.0% of all patients received chemotherapy within 6 months of EOL. Frequency of targeted therapy use across all time points within 6 months of EOL was stable to marginally rising from 2007 to 2013 (Ptrend = .09 to .82; ∆ = -0.2% to 1.8%); overall, 1.2% received targeted therapy within 14 days and 3.6% within 1 month of EOL. By 2013, 13.2% of patients received any targeted therapy within 6 months of EOL. In a multilevel model, 5.19% (intraclass correlation coefficient) of variation in 14-day EOL chemotherapy was attributed to the physician level.
Conclusion: With national benchmarking, chemotherapy within 14 days of EOL successfully declined to less than 5%, with comprehensive benchmark uptake by physicians. Results may inform current strategies to help to achieve high-value EOL oncology practice.
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study.J Clin Oncol. 2012 Dec 10;30(35):4387-95. doi: 10.1200/JCO.2012.43.6055. Epub 2012 Nov 13. J Clin Oncol. 2012. PMID: 23150700 Free PMC article.
Trends in the quality of treatment for patients with intact cervical cancer in the United States, 1999 through 2011.Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):260-7. doi: 10.1016/j.ijrobp.2015.01.037. Int J Radiat Oncol Biol Phys. 2015. PMID: 25968823
End-of-life care discussions among patients with advanced cancer: a cohort study.Ann Intern Med. 2012 Feb 7;156(3):204-10. doi: 10.7326/0003-4819-156-3-201202070-00008. Ann Intern Med. 2012. PMID: 22312140 Free PMC article.
Association between survival time with metastatic breast cancer and aggressive end-of-life care.Breast Cancer Res Treat. 2017 Nov;166(2):549-558. doi: 10.1007/s10549-017-4420-4. Epub 2017 Jul 27. Breast Cancer Res Treat. 2017. PMID: 28752188 Free PMC article.
End of life care for women with gynecologic cancers.Gynecol Oncol. 2010 Aug 1;118(2):196-201. doi: 10.1016/j.ygyno.2010.04.014. Epub 2010 May 13. Gynecol Oncol. 2010. PMID: 20466411 Review.
Cited by 2 articles
Sea Change: A Decade of Intensity-Modulated Radiation Therapy for Treatment of Breast Cancer.J Natl Cancer Inst. 2020 Mar 1;112(3):221-223. doi: 10.1093/jnci/djz199. J Natl Cancer Inst. 2020. PMID: 31647554 No abstract available.
Geriatric oncology health services research: Cancer and Aging Research Group infrastructure core.J Geriatr Oncol. 2020 Mar;11(2):350-354. doi: 10.1016/j.jgo.2019.07.012. Epub 2019 Jul 17. J Geriatr Oncol. 2020. PMID: 31326392 No abstract available.